In recent years, net-zero emissions initiatives, particularly in the pharmaceutical industry, have gained momentum. Traditionally lagging in emissions commitments, Pharma is now under pressure from customers and regulators to focus on reducing emissions.
In this Special Report, we delve deeper into this evolving landscape. Thirteen of the top 20 pharma companies by revenue have committed to net-zero, with over half making these commitments in the past three years. We provide insights into the significance of reducing Scope 3 emissions as an environmental necessity and a key strategic opportunity. We highlight what pharma companies implementing emission reduction initiatives can expect to gain commercially and operationally, enhancing their competitive edge.
Download the Special Report to learn more and get a detailed insight.
03192024090351